- Synta Pharmaceuticals (SNTA) says it's launching its Hsp90-inhibitor Drug Conjugate platform, with the intention of creating a new class of anti-cancer therapies.
- The objective is to create novel drug conjugates that exploit Hsp90 biology to selectively deliver potent anti-cancer payloads to cancer cells.
- The drug developer expects to launch its first investigational new drug in next 18 months.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs